Plant Health Care Plc Overview
Plant Health Care was a small-cap agricultural biologicals company. It owned two protein- and peptide-based technology platforms that act as "vaccines for plants": they trigger a crop's own defence and stress-response pathways rather than killing pests directly. The legacy platform is Harpinαβ, a recombinant protein biostimulant sold as Employ, ProAct, H2Copla and other brands. The newer platform is PREtec (Plant Response Elicitor technology), a family of patented synthetic peptides that has produced registered products including Saori, Obrona, Moshy, Teikko, PREzym and Innocul8. The company had about $11m of revenue and roughly 60% gross margins. It went to market through large distributors (Wilbur-Ellis, Nutrien Ag Solutions, Agrii, AMVAC, Novozymes South Asia) and earned most of its revenue in the US, Brazil, Mexico and Southern Europe. Chronic losses and a thin cash runway led to its 2024 sale to India's PI Industries. It now forms the biologicals technology core of PI AgSciences, PI's global agriculture arm.
Company's own description (latest annual report, FY2023)
The FY2023 Annual Report describes the company as a provider of novel, patent-protected biological products that help farmers feed the world sustainably. It says its proprietary products, derived from natural proteins, protect crops from diseases, nematodes and stress, raising yield, quality and grower returns. (Source: FY2023 Full Year Results, RNS 31 May 2024)
The CODM (chief operating decision maker) managed the business along two strategic lines (FY2023 Note 5):
Commercial: sale of proprietary biological products (Harpinαβ and PREtec) and of third-party biologicals in Mexico. This was the only revenue-generating line and was reported in three geographic segments: Americas (excluding Mexico), Mexico, and Rest of World.
PREtec: research and development of the PREtec peptide platform. This segment had no revenue.
Business model and revenue model
| Dimension | Characterisation (FY2023 evidence) |
|---|---|
| Revenue type | 100% product sales, recognised at a point in time on delivery to the port of departure or arrival (FY2023 Note 3). No subscription, service or royalty revenue was disclosed. |
| Proprietary vs third-party | Proprietary products $8.652m (77%); third-party products $2.554m (23%), almost entirely in Mexico (FY2023 Note 3) |
| Platform mix | Harpinαβ about $6.6–6.7m (≈59–60%); PREtec $2.0m (18%); third-party about $2.6–2.7m (≈23%). The CEO and CFO statements differ slightly; see Section 4. |
| Go-to-market | Mainly exclusive or semi-exclusive distribution agreements with large ag-input distributors. The company said it worked with six of the world's largest distributors, together covering more than 150 million acres of soy, corn and sugar cane (FY2023 CEO statement). |
| Manufacturing | Asset-light. Harpinαβ and PHC279 (the Saori/Obrona active) are made by an EU-based toll fermentation partner. Harpin production moved from China to Europe, which lowered unit costs (FY2023 CFO statement; 2021 supply agreement). |
| Customer concentration | High. In FY2023 one Americas customer was 19% of revenue, another Americas customer 12%, and one Mexico customer 12%. In FY2022 one Americas customer alone was 27% (FY2023 Note 5). |
| Seasonality | FY2023 revenue, gross margin and LBITDA split about 50/50 between halves, which management said was a deliberate goal. US distributor buying cycles nonetheless caused large year-to-year swings. |
Value chain position
PHC sat in the discovery → registration → branded formulation part of the crop-input value chain. It discovered and patented proteins and peptides in its Seattle laboratory, ran field trials, obtained registrations from regulators (EPA/California DPR in the US; MAPA in Brazil; COFEPRIS/SENASICA in Mexico; EU member states), outsourced fermentation, and sold formulated product to distributors. Distributors handled farmer-level sales, agronomy and credit. PHC did not sell directly to growers at scale, except through its Mexican subsidiary, which also sold third-party biologicals.
Customer types and end-markets
Customer types: national and multinational ag-input distributors and retailers (Wilbur-Ellis, Nutrien Ag Solutions, Agrii UK, EDAF Unipessoal in Portugal, Novozymes South Asia, AMVAC China), sugar mills and processors in Brazil, seed-treatment partners, and distributors and growers in Mexico.
Crops and end-markets: US corn (seed treatment) and specialty crops (fruits, nuts, vegetables); Brazilian soybeans (Saori, Teikko), sugar cane (H2Copla, Moshy) and coffee (Moshy); Mexican specialty crops, agave and avocado; UK potatoes and cereals (Innocul8); Iberian fruit, vegetables and cereals (PREzym, Harpinαβ); South African crops; Indian sugar cane; Chinese vegetables and row crops (via AMVAC fertilizer combinations).
Independent characterisation
PHC was a technologically differentiated but sub-scale biologicals developer. It spent more than $100m of shareholder capital over two decades (accumulated deficit of $101.4m at end-FY2023) and never reached sustained profitability. The commercial unit was roughly breakeven at segment level in FY2023 (+$0.26m segment operating profit), but this was outweighed by PREtec R&D (about $3.2m segment loss) and public-company overheads (about $1.7m). Its strategic value lay mainly in its IP-protected peptide discovery engine and global registrations, not in its current earnings. That explains why a well-capitalised strategic buyer (PI Industries) acquired it at roughly 3.6–3.9x trailing sales rather than it continuing as an independent listed company.
Strategy
Stated strategy (FY2021–FY2023 annual reports and investor materials, paraphrased)
-
Scale Harpinαβ through large distributors. Exclusive or semi-exclusive deals with distributors controlling large acreage, giving access to farmers without a direct sales force.
-
Launch one new PREtec product a year from the peptide platform (Trading Statement Feb 2023; FY2023 Annual Report).
-
Geographic diversification. Reduce dependence on the US, expand in Brazil, Mexico, Europe, India and China, and smooth seasonality.
-
Low-cost supply. EU toll fermentation to secure margins (Harpinαβ about 69%, PREtec about 77% gross margin in FY2023).
-
Financial targets. Revenue of $30m by 2025; cash breakeven within existing resources; cash positive and profitable by end-2024 (CEO, June 2023). All were missed or overtaken by the sale.
-
Sustainability positioning. Products framed as reducing reliance on synthetic fertilisers and pesticides and improving resilience to drought and flooding.
Initiatives in the 24 months before the sale (2022–2024)
| Initiative | Date | Detail |
|---|---|---|
| Nutrien Saori agreement | 2,022 | Five-year Brazil soybean supply agreement. Saori revenue was expected to exceed $5m by 2025 (Kalkine, May 2022). |
| ProAct entry into Argentina | 2,022 | First sales |
| India entry | Early 2023 | Novozymes South Asia, exclusive Harpinαβ for sugar cane |
| Obrona US launch | Jun 2023 | With Wilbur-Ellis |
| EU PREtec entry | 2,023 | PREzym (Portugal/Spain, EDAF); Innocul8 (UK, Agrii) |
| AIM listing review | May 2023 | Consultation on whether AIM remained the best market |
| Cost programme | H2 2023 | Opex down 13%; board downsized; capitalisation of development costs |
| Teikko registration and launch | Jan–H2 2024 | Brazil soybean nematicide |
| China entry | Apr 2024 | AMVAC distribution |
| Non-dilutive financing search | May 2024 | Working-capital facility under review; financing secured after year-end referenced in the going-concern note (terms not disclosed) |
Post-acquisition strategy (PI Industries / PI AgSciences)
-
PI said it bought PHC to build a differentiated portfolio of integrated chemical and biological solutions for sustainable agriculture, and to gain access to peptide technology in the "Plant Immunity Inducers" space (PI press release, 26 Jun 2024).
-
In November 2025, PI AgSciences was made the platform for PI's global agriculture business. Its remit extends beyond PHC's legacy biologicals to crop protection, custom synthesis and manufacturing, formulations and branded products (PR Newswire, 24 Nov 2025).
-
PI reported that its biologicals portfolio grew about 20% YoY in FY2024-25, with sustained R&D investment and global partnerships (PI Industries Directors' Report, FY2024-25). PHC's own contribution is not separately disclosed.
Medium-term targets for PI AgSciences: not publicly disclosed.
Products & Services
Harpinαβ platform (Commercial segments)
| Brand | Market | Description / use | Partner | Launch / status |
|---|---|---|---|---|
| Employ® | USA | Harpinαβ for specialty crops (fruits, vegetables, nuts). California approved an expanded crop-group label (2024). | Wilbur-Ellis (exclusive specialty crops) | Long established. Wilbur-Ellis on-ground sales were up more than 75% YoY in early 2024. |
| ProAct® | USA (corn seed treatment); Argentina from 2022 | Harpinαβ for row crops and corn seed treatment | An undisclosed "leading supplier to US corn growers" (exclusive); Argentina distributor not disclosed | Corn agreement gave access to the roughly 90m-acre US corn market |
| H2Copla® | Brazil | Harpinαβ for sugar cane, sold to sugar mills and processors | Brazilian distributors and mills | FY2023 sales +45% to $2.1m; on-ground sales +27% |
| Harpinαβ (various local brands) | Mexico | Specialty crops, agave, avocado; expansion into sugar cane | Plant Health Care Mexico (direct) | Sales +55% in FY2023 |
| Harpinαβ | Spain, Portugal, Southern Europe, South Africa | Fruit, vegetables, field crops | Local distributors; EMEAA team | Sales +16% in FY2023; French registration expected (2024) |
| Harpinαβ | India | Sugar cane | Novozymes South Asia (exclusive) | Agreement early 2023; launch expected 2024 |
| Harpinαβ + AMVAC fertilizer | China | Novel fertilizer combination for vegetables and row crops | AMVAC (via its China subsidiary, Agrinos China) | Agreement 16 Apr 2024; first launches planned for 2024 |
Harpinαβ is a recombinant protein derived from harpin technology acquired from Eden Bioscience in 2007. It acts as a biostimulant that improves crop quality, nutrient use, tolerance to abiotic stress, and yield (FY2023 Annual Report). FY2023 gross margin on Harpinαβ was about 69%, and 68%+ in Mexico. Its 2020–2023 CAGR was about 20%.
Legacy products (historic): Myconate® (a mycorrhizal stimulant, partnered with INCOTEC in 2011), N-Hibit® and PreTect. These are no longer reported as material.
PREtec platform (synthetic peptides, "Vaccines for Plants™")
| Active | Brand | Market | Use | Partner | Registration / launch |
|---|---|---|---|---|---|
| PHC279 | Saori™ | Brazil | Soybean seed treatment and foliar use against Asian soybean rust and other diseases | Nutrien Ag Solutions (5-year agreement, 2022) | Approved Jan 2021. FY2022 sales $0.8m; FY2023 sales +36% to $1.1m. |
| PHC279 | Saori™ | Mexico | Disease control | — | Registered for commercial launch (2024) |
| PHC279 | Obrona™ | USA | Foliar fungicide for fruits, nuts, vegetables, row crops | Wilbur-Ellis | US registration 2023; launched Jun 2023; FY2023 sales $0.6m |
| PHC279 | Moshy® | Brazil | Fungicide for sugar cane and coffee | — | Federal approval 2023; launch planned H2 2024 |
| PHC279 / PREtec | PREzym | Portugal, Spain | Fruit, vegetable and cereal production | EDAF Unipessoal (exclusive Portugal distributor) | First European PREtec sales in 2023; $0.1m FY2023 |
| PREtec (with Agrii micronutrient) | Innocul8 | UK | Potatoes and a range of crops; combined with Agrii's foliar micronutrient | Agrii UK | First sales 2023 ($0.2m); broader launch 2024 |
| PHC68949 (PHC949) | Teikko® | Brazil | Seed-treatment nematicide against root-lesion nematode (Pratylenchus brachyurus) in soybean | About 10 distributors expressed interest; launch partners not disclosed | Federal approval announced 2 Jan 2024, for the 2024/25 season. Brazilian soybean area cited at about 45m ha. |
| PHC949 | (nematicide) | Mexico; USA | Nematode control | — | Mexico approval referenced in FY2023 Annual Report; US application filed (company media page) |
| Innatus 3G family | (licensing candidate) | Global | Corn and other crops | Two majors evaluated it in 2015–2016 | Licensing outcome not disclosed |
PREtec peptides are short synthetic peptides designed to elicit plant immune and stress responses. Management's stated aim was to launch one new PREtec product a year. More than $30m was invested in PREtec over about a decade (FY2023 Chairman's statement). FY2023 PREtec gross margin was about 77%.
Third-party products (Mexico)
Plant Health Care Mexico sells a broad range of third-party biological products alongside proprietary lines. FY2023 third-party revenue was $2.554m, at a gross margin of about 39% (down 5 points). Individual third-party brands are not publicly itemised.
Pricing model
Unit pricing is not publicly disclosed. Products were sold to distributors at invoiced amounts net of rebates and support payments. In FY2022, $1.071m of Americas sales had payment terms longer than 180 days; there were none in FY2023 (FY2023 Note 3).
Financial Narrative
Sources: FY2023 Full Year Results (RNS 31 May 2024); FY2022 results (RNS 2 May 2023) and Alliance News coverage; FY2021 preliminary results and Alliance News (May 2022); FY2019 results (StockMarketWire/AJ Bell, 2020); Trading Statement 6 Feb 2023. Where a figure comes from an aggregator (roic.ai) rather than a filing, this is noted. FY2024 onward: not publicly disclosed.
Income statement
Revenue CAGR FY2019–FY2023: about 15.0% ($6.4m to $11.2m; calculated).
Adjusted LBITDA definition: loss before interest, tax, depreciation, amortisation, share-based payments and FX. The FY2023 reconciliation is: operating loss (4,571) + D&A 725 + SBP 1,009 + FX gain (25) = (2,862). Discrepancy: the FY2023 highlights say "$2.8m" while the CEO statement says "$2.9m"; the reconciliation gives $2.862m. EBITDA on a statutory basis (operating loss + D&A) was -$3.846m in FY2023 and -$8.570m in FY2022 (calculated).
Commentary.
FY2019: revenue fell 21% because Brazilian sales were delayed and US conditions were very difficult. US tariffs on China-sourced Harpin also squeezed margins. This tariff exposure later prompted the move of manufacturing to an EU toll producer.
FY2020–FY2021: a recovery phase. FY2021 revenue rose 28% (24% in constant currency) and gross margin widened about 300bp to 59% on Harpinαβ growth through the US corn and Wilbur-Ellis channels. The pre-tax loss nearly doubled to $6.4m as PREtec investment rose to $3.7m (FY2020: $2.7m).
FY2022 (peak revenue): revenue rose 40% to $11.8m, helped by Saori's first full year ($0.8m) and US corn sales. The reported loss widened to $9.4m. About $3.8m of this was non-cash FX on intra-group Sterling loans, and administrative expense rose 92% to $8.3m.
FY2023 (setback): revenue fell 5% (9% in constant currency) because US distributors destocked heavily and US revenue fell 45% to $2.6m. Outside the US, revenue rose 23%. Cost control cut operating expenses by 13% and the operating loss halved to $4.6m, helped by the hedge-accounting change that removed FX volatility from P&L.
Target miss: management had repeatedly guided to $30m revenue by 2025 (FY2021–FY2023 statements). FY2023 revenue was 37% of that target, and early 2024 trading (Jan–Apr revenue $4.3m, +72% YoY) did not imply the required trajectory.
Balance sheet
FY2021 cash: the $9.16m headline (FY2021 results) included bond and money-market fund investments. IFRS cash and cash equivalents were $1.005m (opening balance in the FY2022 cash-flow statement). FY2022 shows $8.032m of investment sales. FY2019–FY2020 cash figures are from results commentary.
Commentary. The balance sheet was clean (debt was immaterial, consisting mainly of leases and small local borrowings) but cash was thin. Cash fell from $5.7m to $2.1m in FY2023 even after a $3.3m net equity raise. Receivables more than doubled to $3.4m because two North American customers paid late; most of this was collected in January 2024. The going-concern note flagged a material uncertainty: if revenue growth was 25% or less, further funding would be needed and was not assured. The directors listed possible remedies including PREtec cuts, staff reductions, a share placing, non-dilutive financing, or "the potential sale of the Group". The sale to PI followed within weeks.
Cash flow
FY2021 OCF of $3.2m is "cash used in operations" per the 6 Feb 2023 Trading Statement. FCF per share per roic.ai: FY2019 -0.03, FY2020 -0.01, FY2021 -0.01, FY2022 -0.01 USD.
Commentary. Operating cash burn worsened in FY2023 even though the operating loss halved. The cause was working capital: $5.1m was absorbed (FY2022: $3.1m), mainly through higher receivables and lower payables. Over the five years, cumulative operating outflow was about $11.8m for FY2021–FY2023 alone.
Ratios (calculated from reported figures)
ROIC, net debt/EBITDA and interest coverage are not meaningful: EBITDA was negative and the company held net cash. Trade payables of $1.6m (FY2022) and $1.3m (FY2023) are from the CFO narrative.
Commentary. The cash conversion cycle of roughly 6–8 months is long even for crop inputs. It reflects around eight months of inventory cover (fermentation batch economics and seasonal demand) and distributor credit terms. This working-capital intensity, more than the P&L loss, was the binding constraint on PHC's independence.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products |
|---|---|---|
Commercial – Americas | North and South America excluding Mexico (US, Brazil, Argentina) | Harpinαβ (Employ, H2Copla, ProAct), Saori, Obrona |
Commercial – Mexico | Plant Health Care Mexico | Harpinαβ plus a broad third-party biologicals line |
Commercial – Rest of World (EMEAA) | UK and Spanish subsidiaries serving Europe and Southern Africa; India and China via distributors | Harpinαβ, PREzym, Innocul8 |
PREtec | R&D on the PREtec peptide platform (no revenue) | Pipeline peptides |
Unallocated corporate | Public-company costs (wages, professional fees, administration) | — |
Revenue by Segment
| Segment | FY2022 | FY2023 |
|---|---|---|
Americas external revenue (USD Mn) | 7.059 | 5.819 |
Mexico external revenue (USD Mn) | 3.364 | 3.494 |
Rest of World external revenue (USD Mn) | 1.344 | 1.893 |
Total revenue (USD Mn) | 11.767 | 11.206 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2022 | FY2023 |
|---|---|---|
Americas segment operating profit (USD Mn) | 0.322 | -0.099 |
Mexico segment operating profit (USD Mn) | 0.383 | 0.197 |
Rest of World segment operating profit (USD Mn) | -0.109 | 0.162 |
Total Commercial segment operating profit (USD Mn) | 0.596 | 0.260 |
PREtec R&D segment loss (USD Mn) | -3.984 | -3.170 |
Unallocated corporate costs (USD Mn) | -5.850 | -1.661 |
Group operating loss (USD Mn) | -9.238 | -4.571 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 |
|---|---|---|
Americas segment margin on external revenue (%) | 4.6 | -1.7 |
Mexico segment margin (%) | 11.4 | 5.6 |
Rest of World segment margin (%) | -8.1 | 8.6 |
Americas share of group revenue (%) | 60.0 | 51.9 |
Mexico share of group revenue (%) | 28.6 | 31.2 |
Rest of World share of group revenue (%) | 11.4 | 16.9 |
Americas YoY growth (%) | — | -17.6 |
Mexico YoY growth (%) | — | 3.9 |
Rest of World YoY growth (%) | — | 40.8 |
Revenue by Segment (FY2021–FY2023)
| Platform | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Harpinαβ revenue (USD Mn) | — | 8.2 | 6.7 |
PREtec revenue (USD Mn) | — | 0.8 | 2.0 |
Third-party products revenue (USD Mn) | 2.4 | 2.84 | 2.554 |
Income Statement and Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue (USD Mn) | 6.4 | 6.6 | 8.4 | 11.767 | 11.206 |
Revenue growth YoY (%) | -21 | 3 | 28 | 40 | -5 |
Gross profit (USD Mn) | — | — | — | 7.171 | 6.765 |
Gross margin (%) | — | 56 | 59 | 60.9 | 60.4 |
R&D expense (USD Mn) | — | — | — | 3.564 | 2.853 |
Sales and marketing expense (USD Mn) | — | — | — | 4.557 | 4.260 |
Administrative expense (USD Mn) | — | — | — | 8.288 | 4.223 |
Operating loss (USD Mn) | — | — | — | -9.238 | -4.571 |
Operating margin (%) (FY2019–21 per roic.ai) | -64.2 | -58.4 | -75.7 | -78.5 | -40.8 |
Adjusted LBITDA (USD Mn) | — | — | — | -3.686 | -2.862 |
Loss before tax (USD Mn) | -3.8 | -3.3 | -6.4 | -9.447 | -4.489 |
Income tax credit/(expense) (USD Mn) | — | — | — | -0.036 | 0.489 |
Net loss (USD Mn) | — | — | — | -9.483 | -4.000 |
Net margin (%) | — | — | — | -80.6 | -35.7 |
Basic and diluted EPS (USD) (FY2019–21 per roic.ai) | -0.02 | -0.01 | -0.02 | -0.03 | -0.01 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (M) | 178 | 245 | 292 | 305.1 | 325.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Total assets (USD Mn) | — | — | — | 13.824 | 13.489 |
Cash and cash equivalents (USD Mn) | 2.4 | 4.14 | 1.005 | 5.656 | 2.111 |
Cash plus short-term investments (USD Mn) | — | — | 9.16 | 5.656 | 2.111 |
Inventories (USD Mn) | — | — | — | 3.371 | 2.997 |
Trade and other receivables, current (USD Mn) | — | — | — | 1.801 | 4.048 |
Borrowings, current (USD Mn) | — | — | — | 0.055 | 0.269 |
Borrowings, non-current (USD Mn) | — | — | — | 0.215 | 0.210 |
Lease liabilities, total (USD Mn) | — | — | — | 0.629 | 0.679 |
Total debt incl. leases (USD Mn) | — | — | — | 0.899 | 1.158 |
Net cash (USD Mn) (cash less debt incl. leases) | — | — | — | 4.757 | 0.953 |
Total equity (USD Mn) | — | — | 14.358 | 9.690 | 10.225 |
Goodwill (USD Mn) | — | — | 1.620 | 1.620 | 1.620 |
Other intangibles incl. capitalised development (USD Mn) | — | — | 0.003 | 0 | 0.711 |
Working capital (USD Mn) (current assets less current liabilities) | — | — | — | 7.101 | 6.148 |
Accumulated deficit (USD Mn) | — | — | -90.024 | -98.377 | -101.368 |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Net cash from operating activities (USD Mn) | — | — | -3.2 | -2.714 | -5.850 |
Capex – PP&E (USD Mn) | — | — | — | 0.133 | 0.085 |
Capitalised development / intangibles (USD Mn) | — | — | — | 0 | 0.711 |
Free cash flow (USD Mn) (OCF less PP&E and intangibles capex) | — | — | — | -2.847 | -6.646 |
Lease payments (USD Mn) | — | — | — | 0.497 | 0.555 |
Equity issued, net (USD Mn) | — | — | — | 0.026 | 3.311 |
Dividends paid (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 |
|---|---|---|
ROE (%) (net loss / average equity) | -78.9 | -40.2 |
ROA (%) (net loss / average total assets) | — | -29.3 |
Current ratio (x) | 2.91 | 3.04 |
Debt incl. leases / equity (x) | 0.09 | 0.11 |
Asset turnover (x) (revenue / average total assets) | — | 0.82 |
Days sales outstanding (days) (net trade receivables / revenue × 365) | 42 | 106 |
Days inventory outstanding (days) (inventory / cost of sales × 365) | 268 | 246 |
Days payables outstanding (days) (trade payables / cost of sales × 365) | 127 | 107 |
Cash conversion cycle (days) | 183 | 245 |
Revenue by Region
| Country | FY2022 | FY2023 |
|---|---|---|
United States revenue (USD Mn) | 4.817 | 2.634 |
Brazil revenue (USD Mn) | 2.243 | 3.186 |
Mexico revenue (USD Mn) | 3.364 | 3.493 |
Spain revenue (USD Mn) | 1.074 | 1.359 |
United Kingdom revenue (USD Mn) | 0.269 | 0.534 |
Total (USD Mn) | 11.767 | 11.206 |
Region Overview
| Region | FY2023 growth (%) | Primary driver |
|---|---|---|
North America | -45 | Distributor destocking; high interest rates; Harpinαβ NA sales -58% to $2.0m, partly offset by Obrona's first $0.6m |
South America | 42 | H2Copla +45% to $2.1m; Saori +36% to $1.1m |
EMEAA | 41 | Harpinαβ +16% to $1.5m; PREzym ($0.1m) and Innocul8 ($0.2m) launches |
Mexico | 4 | Harpinαβ +55% in specialty crops, agave and avocado; third-party sales hit by weather in north-west Mexico and lower vegetable prices |
Revenue by Region (%)
| Country | FY2022 | FY2023 |
|---|---|---|
United States share (%) | 41 | 24 |
Mexico share (%) | 29 | 31 |
Brazil share (%) | 19 | 28 |
Spain share (%) | 9 | 12 |
United Kingdom share (%) | 2 | 5 |
Segment (FY2023) Overview
| Segment (FY2023) | Proprietary sales (USD Mn) | Third-party sales (USD Mn) | Main geographies |
|---|---|---|---|
Americas | 5.809 | 0.010 | US, Brazil, Argentina |
Mexico | 0.964 | 2.530 | Mexico |
Rest of World | 1.892 | 0.001 | Spain, Portugal, UK, South Africa, India |
FY2017 by Reference Point
| Reference point | FY2017 | FY2020 | FY2023 | FY2024 |
|---|---|---|---|---|
Representative share price (GBp) | 19 | 6.1 | 9.45 | 9.0 |
Performance Details
| Performance | Value |
|---|---|
1-year to completion (Aug 2023–Aug 2024) | About -2.2% (Alliance News) |
3-year / 5-year | Directionally, holders from 2017 (about 19–27p) lost about 55–65% at the 9.0p exit; holders from 2019–2020 (6–7p) made about 30–50%. |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Equity value | £32.8m (≈$41.6m) | Offer terms; USD conversion per US press |
EV / FY2023 sales | About 3.6x | ($41.6m − $0.95m net cash) / $11.2m |
EV / FY2023 gross profit | About 6.0x | $40.6m / $6.77m |
P/B | About 4.1x | $41.6m / $10.2m FY2023 equity |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | None paid (FY2019–FY2023) |
Credit ratings (Moody's, S&P, Fitch) | None; unrated |
Debt maturity profile | FY2023: borrowings $0.269m current and $0.210m non-current; leases $0.633m current and $0.046m non-current. Debt is immaterial. |
Analyst coverage (historic) | Simply Wall St counted 7 covering analysts (e.g., Andrew Simms, Arden Partners). |
Analyst Conclusions
Management guidance
Last standalone guidance (May 2024): significant revenue growth in 2024 in line with market forecasts. The going-concern base case assumed revenue +39% in FY2024 and +55% in H1 2025. Drivers were Teikko and Moshy launches in Brazil, Innocul8 expansion in the UK, entry into India and China, and recovery of US Harpinαβ demand.
Current guidance (PI AgSciences): none disclosed specifically for the former PHC business. PI Industries reported its biologicals portfolio up about 20% in FY2024-25 and pointed to Indian regulatory headwinds in biologicals during FY2025-26.
Consensus
Not applicable (delisted). PI Industries consensus does not separate out PHC.
Bull case
-
Pipeline monetisation under a well-funded owner. Teikko (Brazilian soy, about 45m ha) and Moshy (cane and coffee) can scale now that working capital no longer constrains them. PHC's FY2023 liquidity squeeze was the binding constraint, and PI removed it.
-
Margin leverage. At 69–77% product gross margins, each incremental $10m of proprietary revenue could add about $7m of gross profit against a cost base already partly absorbed by PI's shared services.
-
Distribution amplification. PI's reach into more than 40 countries, plus existing partners (Nutrien, Wilbur-Ellis, AMVAC), could drive the multi-region diversification PHC began (non-US growth was +23% in FY2023).
Bear case
-
Persistent sub-scale economics. Even at its FY2022 peak ($11.8m), PHC made heavy losses. Biologicals adoption is slow; management admitted that adoption of these novel products takes time.
-
Channel and regulatory volatility. US destocking (-45% in FY2023) and Indian biostimulant regulation (cited by PI in 2025) show how exposed this category is to external shocks.
-
Integration risk. Relocating HQ to St. Louis, changing leadership (Tweedy to Rana) and rebranding away from a recognised trade name could erode distributor relationships and lose R&D talent. No post-deal performance data have been disclosed.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| PI Industries FY2025-26 annual report (expected mid-2026; check for subsidiary financials of Plant Health Care plc / PI AgSciences) | First possible look at PHC revenue and losses after the deal, and any goodwill impairment |
| PI quarterly earnings calls (biologicals commentary) | Growth rates, Teikko and Saori traction, regulatory updates |
| UK Companies House filings for Plant Health Care plc / subsidiaries | Statutory accounts for FY2024 and FY2025, re-registration, name changes |
| Teikko label expansions and US nematicide approval | Pipeline value |
| New PREtec registrations (EU, US, Mexico) | Delivery of the one-launch-a-year cadence |
| PI AgSciences leadership and footprint (St. Louis build-out; status of NC office) | Integration health |
Analyst verdict
Plant Health Care is a familiar small-cap story: strong science, weak scale. Over nearly two decades on AIM it built two valuable technology platforms. Harpinαβ, inherited from Eden Bioscience in 2007, delivered a 20% CAGR from 2020 to 2023 and gross margins near 70%. PREtec turned more than $30m of research spending into at least six registered brands on three continents, and its revenue rose 153% in FY2023. Yet the company never converted that technical success into durable economics. Revenue peaked at $23.2m in FY2009, collapsed, and only recovered to $11–12m by FY2022–FY2023. Losses were continuous, the accumulated deficit passed $100m, and the cash conversion cycle of about 245 days kept consuming the equity it raised.
The FY2023 annual report effectively anticipated the outcome. Its going-concern note named a sale of the group as one possible remedy, and within four weeks PI Industries offered 9.0p per share. That was a 57% premium to the market price but only matched the June 2023 placing price, and it valued the business at about 3.6x trailing sales. For shareholders it was a pragmatic exit rather than a triumph. For PI it was a modestly priced entry into peptide-based plant immunity at roughly one-thirtieth of PI's own revenue.
The investment question now sits with PI Industries. Absorbing PHC into PI AgSciences, moving it to St. Louis and appointing a new global biologicals CEO show genuine strategic commitment rather than an asset grab. The constraint that held PHC back, working capital, is gone. What remains unproven is commercial velocity: whether Teikko, Moshy and Obrona can reach material scale and whether distributor relationships survive the integration. Until PI discloses subsidiary-level results, outsiders should treat PHC's technology as strategically promising but financially unproven, and judge the acquisition on PI's biologicals growth and any impairment signals over the next two reporting cycles.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background / education | Source |
|---|---|---|---|---|
Dr Christopher Richards | Non-Executive Chairman | Chairman from Aug 2012; Exec. Chairman & Interim CEO 2017; CEO Nov 2017–Jun 2022; Non-Exec Chairman Jun 2022–Aug 2024 | Held 4,926,527 shares (1.44%) after a Nov 2023 purchase. | RNS 12 May 2022; RNS 24 Nov 2023 |
Jeffrey A. Tweedy | Chief Executive Officer | Joined Oct 2017; COO and Executive Director Nov 2019; CEO from 22 Jun 2022 | 30+ years in technical, product development, sales and executive roles. BSc and MSc, Southern Illinois University Carbondale. Led the distributor strategy (US corn supplier, Wilbur-Ellis, Nutrien) and the Saori launch. | Company board page |
Jeffrey Hovey | Chief Financial Officer and Executive Director | CFO since at least 2017 | — | RNS 2017–2024 |
Kate Coppinger | Non-Executive Director | From Jan 2023 | Investment banking and transaction execution background. Other boards listed: iGas Energy plc, Serica Energy plc, The Barnes Fund Trustee Ltd. | RNS 18 Jan 2023 |
James Ede-Golightly | Non-Executive Director (departed) | Jun 2013–Nov 2016; again Jan 2023–31 Dec 2023 | Professional investor; Executive Chairman of Oxehealth; NED of Silence Therapeutics | RNS 18 Jan 2023; FY2023 Chairman's statement |
Dr Richard Webb | Non-Executive Chairman (departed) | Until AGM 22 Jun 2022 | — | RNS 12 May 2022 |
William Lewis | Non-Executive Director (historic) | At least 2017 | — | RNS Feb 2017 |
Executive Leadership Team
| Name | Role | Source |
|---|---|---|
Jagresh Rana | CEO, PI AgSciences / Global CEO – Biologicals, PI Industries | PI Q1 FY26 call (13 Aug 2025); PR Newswire 24 Nov 2025 |
Wes Hays | Global Marketing Lead, PI AgSciences | Local press, Dec 2025 |
Mayank Singhal | Executive Vice Chairperson and MD, PI Industries (ultimate parent) | PI filings |
Rajnish Sarna | Joint MD, PI Industries | PI filings |
Sanjay Agarwal | Group CFO, PI Industries | PI Q2 FY26 call |
Major Shareholders
| Holder | Shares | % of ISC | Source |
|---|---|---|---|
Ospraie AG Science LLC | 58,072,790 | 17.00 | Company website, data as of 29 Jun 2023 |
Scobie Ward | 38,984,624 | 11.41 | Same |
Richard Griffiths | 36,910,000 | 10.81 | Same (held about 36.7% after the Feb 2018 placing, before later dilution) |
Janus Henderson | 33,322,327 | 9.76 | Same |
Boulder River | 14,059,203 | 4.12 | Same |
Lombard Odier | not stated | 3%+ | Same |
Premier Fund Managers Ltd | 12,661,853 | 3.71 | Same |
Hargreaves Lansdown Stockbrokers (nominee) | 11,123,219 | 3.26 | Same |
Dr Christopher Richards & PCAs | 4,926,527 | 1.44 | RNS 24 Nov 2023 |
Competitive Landscape
Competitors by Segment
| Segment / product area | Competitor | Positioning vs PHC |
|---|---|---|
Plant-defence elicitors / biostimulants (Harpin) | Syngenta Biologicals (incl. Valagro) | Far larger scale and global biostimulant portfolio |
Biostimulants / biologicals | Corteva Biologicals (Stoller, Symborg) | Large biostimulant franchise; strong Latin American presence |
Biologicals (microbial and biochemical) | Novonesis (Novozymes + Chr. Hansen) | Was PHC's India distribution partner (Novozymes South Asia); leader in microbials |
Biologicals / biofungicides | Bioceres Crop Solutions (incl. Rizobacter, ProFarm/Marrone Bio) | Similar biological positioning with greater scale in Argentina and the US |
Biofungicides / bionematicides | Certis Biologicals (Mitsui) | US biological fungicides; direct competitor to Obrona |
Biologicals | Valent BioSciences (Sumitomo Chemical) | Biorationals and plant growth regulators |
Peptide-based crop protection | Vestaron | Peptide insecticides; closest technology analogue (different mode of action) |
Protein-based biocontrols | Biotalys (Belgium) | Protein/peptide biocontrol (Evoca); listed peer |
Natural biopesticides | Eden Research plc (UK, AIM) | AIM-listed biologicals peer (terpenes) |
Biological seed treatments | BASF, Bayer, UPL (NPP) | Integrated biologicals within crop-protection giants |
Nematicides (Teikko) | Chemical nematicides (e.g., fluopyram-based) and biological nematicides from majors | Teikko is positioned as a non-toxic alternative |
Competitor Detail
| Metric | Plant Health Care (FY2023) |
|---|---|
Revenue | $11.2m |
Revenue growth | -5% |
Gross margin | 60.4% |
R&D intensity | 25.5% of revenue |
Profitability | Operating loss -$4.6m |
Recent Developments
Disclosure note: after delisting in August 2024, PHC stopped issuing regulatory announcements. January 2024 to October 2026: the final eight months as a listed company plus all identifiable post-acquisition items.*
